[ ¹⁷⁷ Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.

Autor: Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia. Electronic address: louise.emmett@svha.org.au., Subramaniam S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, NSW, Australia., Crumbaker M; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia; Macquarie University Hospital, Sydney, NSW, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia., Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia., Weickhardt A; Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Lee ST; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; Department of Medicine and Department of Surgery, University of Melbourne, Melbourne, VIC, Australia., Ng S; Department of Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia; Department of Oncology, University of Western Australia, Perth, WA, Australia., Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia., Goh JC; Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Queensland University of Technology, Brisbane, QLD, Australia., Pattison DA; Department of Nuclear Medicine and Specialised PET Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia., Tan TH; Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia., Kirkwood ID; Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia., Gedye C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia., Rutherford NK; Department of Nuclear Medicine, Hunter New England Health, Newcastle, NSW, Australia., Sandhu S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Kumar AR; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Pook D; Department of Oncology, Monash Health, Melbourne, VIC, Australia., Ramdave S; Monash Health Imaging, Monash Health, Melbourne, VIC, Australia., Nadebaum DP; Department of Oncology, Alfred Health, Melbourne, VIC, Australia., Voskoboynik M; Department of Oncology, Alfred Health, Melbourne, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, Australia., Redfern AD; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia., Macdonald W; Medical School, University of Western Australia, Perth, WA, Australia; Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, WA, Australia., Krieger L; Genesis Care North Shore, Sydney, NSW, Australia., Schembri G; Nuclear Medicine, Royal North Shore Hospital, Sydney, NSW, Australia., Chua W; Department of Medical Oncology, Liverpool Hospital, Sydney, NSW, Australia; Western Sydney University, Sydney, NSW, Australia., Lin P; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia; Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, NSW, Australia., Horvath L; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Bastick P; Department of Medical Oncology, St George Hospital, Sydney, NSW, Australia., Butler P; Department of Nuclear Medicine, St George Hospital, Sydney, NSW, Australia., Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Macquarie University Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Yip S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Thomas H; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Langford A; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Hofman MS; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., McJannett M; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia., Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Davis ID; Monash University Eastern Health Clinical School, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 May; Vol. 25 (5), pp. 563-571. Date of Electronic Publication: 2024 Apr 12.

Overall survival with [ ¹⁷⁷ Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.

Autor: Hofman MS; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia. Electronic address: michael.hofman@petermac.org., Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia., Sandhu S; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Iravani A; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Buteau JP; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia., Goh JC; Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Queensland University of Technology, Brisbane, QLD, Australia., Pattison DA; Department of Nuclear Medicine and Specialised PET Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia., Tan TH; Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia., Kirkwood ID; Department of Nuclear Medicine and PET, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia., Ng S; Department of Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia., Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia., Gedye C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia., Rutherford NK; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia; Department of Nuclear Medicine, Hunter New England Health, New Lambton, NSW, Australia., Weickhardt A; Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Scott AM; Department of Medicine, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Lee ST; Department of Medicine, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Kwan EM; Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia., Azad AA; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Ramdave S; Monash Health Imaging, Monash Health, Melbourne, VIC, Australia., Redfern AD; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia., Macdonald W; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia; Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, WA, Australia., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia., Hsiao E; Department of Nuclear Medicine and PET, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia., Chua W; Department of Medical Oncology, Liverpool Hospital, Sydney, NSW, Australia., Lin P; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia; Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, NSW, Australia., Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Macquarie University Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Williams SG; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia., Martin AJ; Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Davis ID; Monash University Eastern Health Clinical School, Melbourne, VIC, Australia; Eastern Health Department of Cancer Services, Eastern Health, Melbourne, VIC, Australia.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Jan; Vol. 25 (1), pp. 99-107. Date of Electronic Publication: 2023 Nov 30.

⁶⁸ Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer.

Autor: Davies A; Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia., Foo M; GenesisCare, Melbourne, Victoria, Australia., Gan CL; Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia.; Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada., Kourambas J; Department of Urology, Monash Health, Melbourne, Victoria, Australia., Redgrave N; Department of Urology, Monash Health, Melbourne, Victoria, Australia., Donnellan S; Department of Urology, Monash Health, Melbourne, Victoria, Australia., Appu S; Department of Surgery, Monash Health, Melbourne, Victoria, Australia., Williams S; Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia., Coleman A; Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Segelov E; Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia.; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia., Bradley J; Department of Nuclear Medicine & PET, Monash Health, Melbourne, Victoria, Australia., Soo G; Department of Nuclear Medicine & PET, Monash Health, Melbourne, Victoria, Australia., Ramdave S; Department of Nuclear Medicine & PET, Monash Health, Melbourne, Victoria, Australia., Kwan EM; Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia.; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia., Azad AA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Publikováno v: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Oct; Vol. 18 (5), pp. e204-e210. Date of Electronic Publication: 2021 Jun 23.

Neurolymphomatosis: an uncommon manifestation of lymphoma - detection and therapeutic monitoring through 18F-fluorodeoxyglucose positron-emission tomography and computed tomography imaging.

Autor: Hui SY; Monash Imaging, Monash Health, Clayton, Victoria, Australia., Wong A; Monash Imaging, Monash Health, Clayton, Victoria, Australia., Nambiar M; Monash Imaging, Monash Health, Clayton, Victoria, Australia mithunnambiar1@gmail.com., Ramdave S; Monash Imaging, Monash Health, Clayton, Victoria, Australia.

Publikováno v: BMJ case reports [BMJ Case Rep] 2022 May 10; Vol. 15 (5). Date of Electronic Publication: 2022 May 10.

⁶⁸ Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer.

Autor: Xue AL; Department of Surgery, Monash University, Melbourne, Australia.; Australian Urology Associates, Malvern, Australia., Kalapara AA; Department of Surgery, Monash University, Melbourne, Australia.; Australian Urology Associates, Malvern, Australia.; Department of Urology, University of Minnesota, Minneapolis, Minnesota., Ballok ZE; Healthcare Imaging Services, Richmond, Australia.; Department of Imaging, Monash University, Melbourne, Australia., Levy SM; Cabrini Institute, Cabrini Health, Malvern, Australia.; Department of Nuclear Medicine & PET, Monash Medical Centre, Bentleigh East, Australia.; Department of Imaging, Monash University, Melbourne, Australia., Sivaratnam D; Cabrini Institute, Cabrini Health, Malvern, Australia., Ryan A; TissuPath, Mount Waverley, Australia., Ramdave S; Department of Nuclear Medicine & PET, Monash Medical Centre, Bentleigh East, Australia., O'Sullivan R; Healthcare Imaging Services, Richmond, Australia., Moon D; Department of Surgery, Monash University, Melbourne, Australia.; Australian Urology Associates, Malvern, Australia., Grummet JP; Department of Surgery, Monash University, Melbourne, Australia.; Australian Urology Associates, Malvern, Australia., Frydenberg M; Department of Surgery, Monash University, Melbourne, Australia.; Australian Urology Associates, Malvern, Australia.; Cabrini Institute, Cabrini Health, Malvern, Australia.

Publikováno v: The Journal of urology [J Urol] 2022 Feb; Vol. 207 (2), pp. 341-349. Date of Electronic Publication: 2021 Sep 21.